Q-omics provides the consensus-scored RUNX2 profile across patient tissues and cancer cell-line models. RUNX2 expression is associated with patient survival in 32 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RUNX2 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, RUNX2 RNA expression shows 21,630 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, THCA, and GBM as cancer lineages where RUNX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RUNX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RUNX2 survival associations across molecular data types. RUNX2 RNA expression shows survival associations in the most cancer types (32), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RUNX2 RNA expression–survival associations across cancer types. High RUNX2 expression shows unfavorable associations in KICH, UVM, BLCA, STAD and ACC, but favorable associations in SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RUNX2 RNA expression.
This table summarizes RUNX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RUNX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RUNX2 shows higher tumor expression in THCA, LUAD, KIRC, LUSC, BRCA and BLCA. The THCA box plot shows higher RUNX2 RNA expression in tumor versus normal tissue (log2 FC = +2.215, t-test p < 0.001).
This table shows molecular features associated with RUNX2 in patient tissues and cancer cell lines. In patient samples, RUNX2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RUNX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
